Selective non-competitive AMPA receptor antagonist (IC50
values are 10-20, ~ 450 and >> 50 μ
M for AMPA-, kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. Has anti-proliferative effects in transformed cells. Also available as part of the AMPA Receptor Tocriset™
. Also available as part of the Kainate Receptor Tocriset™
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/kainate receptor responses.
Donevan and Rogawsk
Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons.
Paternain et al.
Glutamate antagonists limit tumor growth.
Rzeski et al.
Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655.
Szabados et al.
Brain Res.Bull., 2001;55:387
Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466.
Tarnawa et al.
The citations listed below are publications that use Tocris products. Selected citations for GYKI 52466 dihydrochloride include:
Showing Results 1 - 9 of 9